Marker Therapeutics
(NASDAQ) MRKR
Marker Therapeutics Financials at a Glance
Market Cap
$22.34M
Revenue (TTM)
$3.55M
Net Income (TTM)
$12.16T
EPS (TTM)
$-0.91
P/E Ratio
-1.47
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$1.34
Volume
1,440
Open
$1.32
Price
$1.34
Volume
1,440
Open
$1.32
Previous Close
$1.34
Daily Range
$1.30 - $1.38
52-Week Range
$0.81 - $4.07
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$1.34
Volume
1,440
Open
$1.32
Previous Close
$1.34
Daily Range
$1.30 - $1.38
52-Week Range
$0.81 - $4.07
MRKR News
MRKR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Marker Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
5
CEO
Juan F. Vera, MD
Website
www.markertherapeutics.comHeadquarters
Houston, TX 77027, US
MRKR Financials
Key Financial Metrics (TTM)
Gross Margin
-1%
Operating Margin
-4%
Net Income Margin
-3429590%
Return on Equity
-69%
Return on Capital
-0%
Return on Assets
-64%
Earnings Yield
-68.03%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$22.34M
Shares Outstanding
16.67M
Volume
1.44K
Short Interest
0.00%
Avg. Volume
311.84K
Financials (TTM)
Gross Profit
$0.00
Operating Income
$12.44M
EBITDA
$12.89T
Operating Cash Flow
$12.01T
Capital Expenditure
$0.00
Free Cash Flow
$12.01T
Cash & ST Invst.
$16.07T
Total Debt
$0.00
Marker Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.10M
-51.0%
Gross Profit
$0.00
+100.0%
Gross Margin
0.00%
N/A
Market Cap
$22.34M
N/A
Market Cap/Employee
$4.47M
N/A
Employees
5
N/A
Net Income
$12.16T
-316956682.1%
EBITDA
$12.89T
-333825668.6%
Quarterly Fundamentals
Net Cash
$16.07T
+83720615.0%
Accounts Receivable
$1.37M
-41.7%
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-63.78%
N/A
Return on Invested Capital
-0.00%
N/A
Free Cash Flow
$12.01T
-255448040.1%
Operating Cash Flow
$12.01T
-255448040.1%